Company: OPGN
Filing Date: 2025-08-21
Form Type: 10-K
Source: 0001829126-25-006628
Chunk: 1791

Company: OPGEN INC
Filing Date: 2025-08-21
Form: 10-K
Item: Item 9C
Chunk 1791
---
 plus the dilutive impact of all potential dilutive common shares, consisting primarily of common shares underlying common stock options and stock purchase warrants using the treasury stock method, and preferred stock using the if-converted method.

    F-18

The Company has calculated basic and diluted earnings (loss) per share for the years ended December 31, 2024 and 2023 as follows:

    Schedule of earnings per share, basic and diluted

    Basic

    Diluted

    Year ended December 31,

    Year ended December 31,

    2024

    2023

    2024

    2023

    Net income (loss)
     
    $
    11,992,780

    $
    (32,668,530
    )
     
    $
    11,992,780

    $
    (32,668,530
    )
  
    Net income allocated to preferred stockholders

    (636,742
    )

    -

    -

    -

    Net income (loss) available to common stockholders
     
    $
    11,356,038

    $
    (32,668,530
    )
     
    $
    11,992,780

    $
    (32,668,530
    )

    Basic weighted average shares outstanding

    4,655,225

    787,832

    4,655,225

    787,832

    Dilutive effect of preferred stock

    564,677

    -

    Dilutive weighted average shares outstanding

    5,219,902

    787,832

    Earnings (loss) per share
     
    $
    2.44

    $
    (41.47
    )
     
    $
    2.30

    $
    (41.47
    )

The number of anti-dilutive shares consisting of shares of common stock underlying (i) common stock options, (ii) restricted stock units, (iii) preferred stock, and (iv) stock purchase warrants, which have been excluded from the computation of diluted income per share was 1.3 million and 1.2 million as of December 31, 2024 and 2023, respectively.

Adopted accounting pronouncements

In January 2024, the Company adopted Accounting Standards Update (ASU) 2023-07, Improvements to Reportable Segment Disclosures (Topic